FCSC Overview
Upcoming Projects (FCSC)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (FCSC)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (FCSC)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (FCSC)
-
Phase 1/2 updated data of Fibrocell's (FCSC) FCX-007 in Recessive dystrophic epidermolysis bullosa due March 27, 2019.
Ticker: FCSC
Occurred on: Mar 27, 2019 -
Fibrocell (FCSC) to submit IND to FDA in fourth quarter of 2017 for FCX-013, a gene therapy treatment for linear scleroderma
Ticker: FCSC
Occurred on: Feb 05, 2018 -
Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary Endpoints
Ticker: FCSC
Occurred on: Jun 08, 2016 -
Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia
Ticker: FCSC
Occurred on: Apr 21, 2016 -
Fibrocell and Intrexon Announce Collaboration to Address Chronic Inflammatory and Degenerative Diseases of the Joint
Tickers: FCSC, XON
Occurred on: Jan 04, 2016
Strategic Initiatives (FCSC)
-
Fibrocell (FCSC) to Collaborate with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
Tickers: FCSC, Castle Creek Biosciences
Announcement Date: Apr 15, 2019
